

CURRENT REPORT

Report date: **05.06.2026**

Name of issuing company: **Antibiotice S.A.**

Headquarters: **Iași, str. Valea Lupului nr. 1, zip code 707410**

<https://www.antibiotice.ro>

E-mail: **relatiicuinvestitorii@antibiotice.ro**

Telephone/fax no. : **+40232 209 000 / +40372 065 633**

Unique registration code in the Trade Register Office: **RO1973096**

No. in the Trade Register: **J1991000285223**

Subscribed and paid-up capital: **67,133,804 LEI**

The regulated market trading on which the securities are issued: **Bucharest Stock Exchange**

Number of shares: **671,338,040**

Number of votes: **671,338,040**

Main characteristics of the securities issued by the company: **nominative shares, nominal value: 0.10 lei**

Antibiotice strengthens its international growth: sales advance in the US and entry into a new market in Europe

- ***the relaunch of sales on the United States market - an estimated growth of 25% in 2026***
- ***the strengthening of its presence in Europe by accessing the Spanish pharmaceutical market - 5 million euros***

Antibiotice experiences a significant progress in the implementation of its internationalization strategy, marked by the relaunch of sales growth on the United States market and the strengthening of its presence in Europe by accessing new pharmaceutical market. These results confirm Antibiotice's competitiveness in mature markets and support the consolidation of its position as a competitive pharmaceutical manufacturer at an international level.

The exports to the United States resume a positive momentum with an estimated growth of 25% in 2026

The United States is one of the strategic markets for Antibiotice's international development, currently contributing approximately by 15% to the company's exports. At the end of May 2026, Antibiotice's main distributor in the US successfully completed the audit carried out at the company's production facilities in Iași, reconfirming its compliance with the high quality and compliance standards imposed by the American market.

The audit result validates the continuity of a strategic partnership developed over 13 years, constantly strengthened by increasing the volumes sold.

After the temporary adjustment recorded in 2025, driven by uncertainties in the commercial and regulatory environment, Antibiotice's exports to the United States returned to an upward trend in 2026, resuming the positive dynamics characteristic

of the 2020-2024 period. In the context of stabilizing market conditions and maintaining solid demand for critical medicines, Antibiotice estimates an increase of approximately 25% in its sales of finished products to the American market in 2026 compared to the previous year.

This development supports favorable prospects for strengthening Antibiotice's position on one of the most important and demanding pharmaceutical markets in the world.

Antibiotice is present on the American market with a portfolio consisting of eight sterile injectable anti-infective products and the Nystatin active ingredient, used in the manufacture of antifungal products.

For over a decade, Antibiotice SA has maintained its position as the world leader in the production of the Nystatin active ingredient and since 2017, the Nystatin produced by our company is recognized by the United States Pharmacopeia (USP) as an international reference standard for quality.

The entry on the Spanish market with cardiovascular medicines
Antibiotice is also enhancing its presence on the European market by entering the Spanish market, one of the most competitive pharmaceutical markets in Europe. The company will introduce three medicinal products for the treatment of cardiovascular diseases on the Spanish market through a reference partner in the Spanish pharmaceutical retail.

The partnership is regulated by a multi-annual contract with an initial duration of 3 years and it allows for the expansion of the contracted volumes depending on the market evolution. The first delivery was made at the end of May and by the end of the contract, the value of deliveries will be approximately 5 million euros.

This partnership opens new opportunities for strengthening Antibiotice's presence in the Spanish market and lays the groundwork for expansion into new international territories through the partner's global network, present in over 100 countries.

The strengthening of the company's international presence and growth prospects
At the end of 2025, the export sales represented approximately 41% of Antibiotice's turnover, confirming the strategic role of foreign markets in the company's development. After the first quarter of 2026, the sales of finished products and active substances reached USD 15.8 million, a level close to that recorded in the previous year, despite an international context experiencing heightened volatility, pricing pressure and increasing operational costs.

The upward trend in sales in the United States, the expansion of the company's presence in Europe - a region that currently generates approximately 50% of finished product, as well as the continuous development of the international project portfolio, support favorable prospects for speeding up the company's external development and strengthening the value created for shareholders in the long term.

General Director,
Ioan NANI, Economist

